aTyr Pharma/$ATYR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About aTyr Pharma
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Ticker
$ATYR
Sector
Primary listing
Employees
61
Headquarters
Website
aTyr Pharma Metrics
BasicAdvanced
$77M
-
-$0.84
0.57
-
Price and volume
Market cap
$77M
Beta
0.57
52-week high
$7.29
52-week low
$0.68
Average daily volume
6.7M
Financial strength
Current ratio
6.115
Quick ratio
5.82
Long term debt to equity
13.655
Total debt to equity
15.44
Profitability
EBITDA (TTM)
-77.978
Gross margin (TTM)
-32,297.89%
Net profit margin (TTM)
-39,537.89%
Operating margin (TTM)
-41,395.26%
Management effectiveness
Return on assets (TTM)
-49.59%
Return on equity (TTM)
-103.49%
Valuation
Price to revenue (TTM)
369.624
Price to book
0.96
Price to tangible book (TTM)
0.96
Price to free cash flow (TTM)
-1.114
Free cash flow yield (TTM)
-89.73%
Free cash flow per share (TTM)
-0.706
Growth
Revenue change (TTM)
-19.15%
Earnings per share change (TTM)
-9.70%
3-year earnings per share growth (CAGR)
-20.07%
10-year earnings per share growth (CAGR)
-33.77%
What the Analysts think about aTyr Pharma
Analyst ratings (Buy, Hold, Sell) for aTyr Pharma stock.
aTyr Pharma Financial Performance
Revenues and expenses
aTyr Pharma Earnings Performance
Company profitability
aTyr Pharma News
AllArticlesVideos
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
Newsfile Corp15 hours ago
UPCOMING DEADLINE: Faruqi & Faruqi Reminds aTyr Pharma Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 - ATYR
Newsfile Corp16 hours ago
Investor Alert: Deadline Approaching to Join aTyr Pharma, Inc. (ATYR) Class Action - Contact Levi & Korsinsky
Newsfile Corp1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for aTyr Pharma stock?
aTyr Pharma (ATYR) has a market cap of $77M as of November 12, 2025.
What is the P/E ratio for aTyr Pharma stock?
The price to earnings (P/E) ratio for aTyr Pharma (ATYR) stock is 0 as of November 12, 2025.
Does aTyr Pharma stock pay dividends?
No, aTyr Pharma (ATYR) stock does not pay dividends to its shareholders as of November 12, 2025.
When is the next aTyr Pharma dividend payment date?
aTyr Pharma (ATYR) stock does not pay dividends to its shareholders.
What is the beta indicator for aTyr Pharma?
aTyr Pharma (ATYR) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.